Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational ...

OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their ...

D Molecular Therapeutics remains a Buy as 4D-150 enters phase 3 for wet AMD/DME, cutting injections up to 87%. Click for more ...

Two investigational agents from Kodiak Sciences helped improve vision in patients with wet age-related macular degeneration, ...

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and ...

Kodiak Sciences announced that Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer (tabirafusp-ted/KSI-501) both met their primary endpoints in the pivotal Phase 3 DAYBREAK study evaluating ...

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

Kodiak Sciences shares surged 143% after the biotech said Zenkuda and tabirafusp-ted met key Phase 3 goals in wet age-related macular degeneration, though full data and regulatory review remain ...

Small overall risk is potentially explained by known AMD risk factors and confounding vari ...

Age-related macular degeneration (AMD) is an eye condition that can affect central vision, which is the vision used for activities such as reading and recognizing faces. In people with wet AMD, ...

Wet age-related macular degeneration (AMD), or advanced neovascular AMD, affects central vision and can lead to rapid, irreversible vision loss. It often requires treatment to preserve eyesight.

Every day tech, like your smartphone or computer, can help manage wet AMD through built-in accessibility features such as voice commands, screen magnification, and high-contrast settings.